{"entity":{"id":"nct01054079","kind":"trial","name":"Cinacalcet Hydrochloride in Treating Men With Recurrent Prostate Cancer","aka":[],"tldr":"A phase 2 trial of Cinacalcet in Prostate cancer, run by Wake Forest University Health Sciences, completed.","summary":"Cinacalcet Hydrochloride in Treating Men With Recurrent Prostate Cancer is a phase 2 interventional study registered as NCT01054079 by Wake Forest University Health Sciences, with 20 participants recorded, started 2011-09 and reaching its primary completion in 2014-08. Interventions recorded: laboratory biomarker analysis, quality-of-life assessment, questionnaire administration, cinacalcet hydrochloride. Conditions recorded: Adenocarcinoma of the Prostate, Recurrent Prostate Cancer.\n\nLinked to the drug Cinacalcet because the registry names it among its interventions and Prostate cancer among its conditions. Registry record only: no result has been read by an editor.","status":"completed","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT01054079","url":"https://clinicaltrials.gov/study/NCT01054079"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["prostate","prostate-bcr"],"sections":[],"technologies":[],"targets":[],"drugs":["cinacalcet"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT01054079","phase":"2","setting":"A Phase II Trial to Assess the Effect of Cinacalcet Hydrochloride on PSA Levels in Patients With Biochemically Recurrent Prostate Cancer After Failed Definitive Local Therapy","sponsor":"Wake Forest University Health Sciences","participation":[{"nct":"NCT01054079","source":"https://clinicaltrials.gov/study/NCT01054079","fetchedAt":"2026-10-07T16:52:19.239Z","studySha256":"9ebdb6767e7ca26a7b18b7cfea1aa4b6acf8292e9ff502c613310b5fc0eac62a","overallStatus":"COMPLETED","lastUpdatePosted":"2018-07-05","leadSponsor":"Wake Forest University Health Sciences","collaboratorCount":1,"minimumAge":"18 Years","sex":"MALE","healthyVolunteers":false,"hasEligibility":true,"enrolment":20,"enrolmentType":"ACTUAL","siteCount":1,"recruitingSiteCount":0,"countries":["United States"]}],"started":"2011-09","yearReported":2015,"enrolled":20,"enrolledBasis":"registry","outcomes":[{"endpoint":"Rate of Rise of Serum PSA","primary":true,"unit":"nanograms per milliliter","arms":[{"name":"Treatment (Cinacalcet Hydrochloride)","n":10,"value":0.0825,"note":"IQR -0.01 to 0.17; Figures from the ClinicalTrials.gov results section (first posted 2015-10-29), not from a publication"}],"source":"https://clinicaltrials.gov/study/NCT01054079?tab=results"}]},"route":"/trials/nct01054079/","neighbours":{"cancer":[{"id":"prostate-bcr","kind":"cancer","name":"Biochemical recurrence of prostate cancer","route":"/cancers/prostate-bcr/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"drug":[{"id":"cinacalcet","kind":"drug","name":"Cinacalcet","route":"/drugs/cinacalcet/"}]}}